←
Brittney Cotta, MD269 posts
Brittney Cotta, MD avatar✓

Brittney Cotta, MD ✓

@BCottaMD

Urologic Oncologist @MDAndersonnews •by way of @UCSD_Urology @UrologyMSK @UMichUrology

◷ Joined December 2018▧ 26 Photos and videos
Brittney Cotta, MD avatar
Brittney Cotta, MD@BCottaMD·Jul 18

Have any other doctors here had their identify stolen to create fake social media pages for a scam? I have had over 20 pages on Facebook using my picture, name, and institution created to sell penis pills and Meta has refused to take them down when I report them.

Brittney Cotta, MD avatar
Brittney Cotta, MD@BCottaMD·Sep 10

Months later and the scam pages are still up and active on @Meta platforms. “Patients” communicating and sending money to scammers and calling my office asking for “me.” No legal recourse unfortunately.

MCG Urology avatar
⟳ Brittney Cotta, MD retweeted
MCG Urology@mcg_urology·Aug 30

Help is on the way!

0:06
Brittney Cotta, MD avatar
Brittney Cotta, MD@BCottaMD·Jul 18

To clarify: I have contacted the relevant authorities and have an attorney. I encourage others to search for fake profiles under their name. This is rampant and many don’t realize.

Kidney Cancer avatar
⟳ Brittney Cotta, MD retweeted
Kidney Cancer@KidneyCancer·Jun 24

📢 Calling all aspiring kidney cancer leaders! Apply for the KCA Mentorship Academy or the Dr. Nizar Tannir Rare Kidney Cancer Scholar Program and accelerate YOUR path to leadership. ⏰Apps due Aug 31 🔗appv2.sessionboard.com/submi…

Post attachment
European Urology Oncology avatar
⟳ Brittney Cotta, MD retweeted
European Urology Oncology@EurUrolOncol·May 4

🎆Editor's Choice! 📝"Current risk stratification for non-clear cell renal cell carcinoma (nccRCC) is largely derived from clear cell RCC (ccRCC) data. We evaluated recurrence patterns following surgery for nccRCC and compared the prognostic performances of various international guidelines." 🩺Beyond Clear Cell: Rethinking Postoperative Surveillance for Non-clear Cell Renal Cell Carcinoma Subtypes by Arighno Das et al 🔎Read the full article on our website: buff.ly/Z1AHFP7 ❗Disclaimer: The clinical relevance on this post was summarised for social media - refer to the full clarification on the article. 🙌We thank the authors for trusting EUO to publish your work! @ArighnoD @BCottaMD @SurenaMatinMD @uroweb @mroupret @GPloussard @jteoh_hk @Ric_Campi @CaPsurvivorship @LauraMarandino @RenuEapen @Ecastromarcos @OncoAlert @Sciencedirect

0:05
KidneyCAN avatar
⟳ Brittney Cotta, MD retweeted
KidneyCAN@kidneycan·Mar 8

Today, on #InternationalWomensDay, we recognize the women affected by #KidneyCancer, as patients, caregivers, researchers, and advocates. While kidney cancer is more common in men, thousands of women are diagnosed each year, and outcomes can vary based on stage, access to care, and participation in clinical research. Women remain underrepresented in some areas of research, making awareness and inclusion especially important. #AcceleratingCures #KidneyCancerAwarenessMonth

Post attachment
Brittney Cotta, MD avatar
Brittney Cotta, MD@BCottaMD·Feb 11

Using paired treatment-naïve primary tumors and asynchronous metastases, we found higher Treg infiltration in primary tumors and site-specific pathway differences across metastases. Grateful to my co-authors, collaborators, and mentors for their support and contributions.